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Objectives. We studied rejection, allograft function and side 
effects, such as hypertension, renal dysfunction and hypercholes- 
terolemia, in seven patients switched from cyclosporine-based 
triple-drug immunosuppression to FK 506. 
Background. A subset of pediatric heart transplant recipients 
treated with triple-drug immunosuppression consisting of cyclo- 
sporine, azathioprine and prednisone xperience ither persistent 
rejection when attempts are made to taper corticosteroids or 
morbidity from cyclosporine and corticosteroids. Experience with 
the new immunosuppressive agent FK 506 has demonstrated its 
effectiveness as a single agent in heart transplant recipients, and 
anecdotal evidence has shown that side effects such as hyperten- 
sion and hypercholesterolemia may be lower. 
Methods. Seven patients whom we deemed corticosteroid de- 
pendent were switched to FK 506-based therapy. Allograft func- 
tion, episodes of rejection, need for corticosteroids and incidence 
of side effects from FK 506 were monitored. The switch to FK 506 
was performed using an established protocol. Follow-up time has 
ranged from 15 to 41 months. Serial right heart catheterizations 
and endomyocardial biopsies were performed after each reduction 
of corticosteroid osing. 
Results. Catheterization data showed no significant change in 
pulmonary wedge pressure, mean right atrial pressure or cardiac 
index, indicating no decline in allografl function. Serial echocar- 
diographic variables of allograft function were also stable. At 
present, all seven patients are free of the corticosteroid portion of 
their immune suppression. There have been only two episodes of 
significant acute rejection requiring treatment with intravenous 
corticosteroids. Antihypertensive medications have been discon- 
tinued in five of six patients previously treated with these drugs. 
Plasma cholesterol, ow density lipoprotein and triglyceride levels 
were decreased, and renal function was stable. 
Conclusions. Preliminary studies suggest hat FK 506 may be 
an alternative immunosuppressive agent for pediatric and adoles- 
cent patients experiencing ongoing rejection or significant mor- 
bidity from cyclosporine and corticosteroids and in those patients 
dependent on corticosteroids for immune suppression. 
(J Am Coil Cardiol 1995;25:1183-8) 
Triple-drug immunosuppression regimens including cyclospo- 
rine, azathioprine and prednisone have greatly improved sur- 
vival after cardiac transplantation in children. Despite the 
success of this regimen, there are patients who experience 
persistent focal graft rejection (International Society of Heart 
and Lung Transplantation [ISHLT] grades 2, 3A and 3B) when 
corticosteroids are tapered or discontinued. In addition, some 
patients experience adverse ffects related to the cyclosporine 
and prednisone combinations, uch as hypertension, hyperlip- 
idemia, migraine headaches, obesity, Cushingoid appearance 
and behavioral changes (1-5). Studies in adult and pediatric 
patients have suggested that side effects, such as hypertension, 
obesity and hypercholesterolemia, may jeopardize long-term 
allograft function and increase the likelihood for the develop- 
ment of obliterative coronary artery disease (6-8). 
Since 1989, FK 506-based immune suppression has been 
used for pediatric heart transplant recipients in Pittsburgh 
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(9,10). This newer immunosuppressive agent has a mechanism 
similar to that of cyclosporine, involving suppression of cyto- 
kine gene transcription and prevention of T-cell activation 
(11). Early in that experience, we found that FK 506 alone was 
as effective as the triple-drug regimen for maintenance therapy 
in most patients. Our management philosophy has always been 
to eliminate corticosteroids from the immune suppression 
regimen as soon after transplantation as feasible. The purpose 
of the present study was to determine the effectiveness of FK 
506 with or without azathioprine for preventing rejection while 
maintaining overall graft function. A subset of pediatric and 
adolescent heart transplant recipients who had persistent 
rejection or morbidity related to the cyclosporine and pred- 
nisone combination was selected for this investigation. 
Methods  
Study patients. The study included seven pediatric and 
young adult patients, 8.9 to 20.5 years old at the time study, 
who had previously undergone orthotopic heart transplanta- 
tion between ages 1.1 and 16.3 years. Transplantation was 
performed at the University of Pittsburgh between January 
1987 and July 1989. All patients originally had induction 
therapy with antithymocyte globulin (rabbit) and maintenance 
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Table I. Demographic Information and Reason for the Switch to FK 506 in the Study Patients 
Pt No./'Age at Reason for CyA Levels Before Switch Time From Tx to 
Tx (yr) Immunnsuppression Switch (ng/ml) Switch (mo) 
I/11.6 Chronic rejection FPIA 1,091, HPLC 233 9 
2/11.11 Chronic rejection FPIA 696, HPLC 193 15 
3/16.3  Corticostcroid morbidly': hyperlipidemia FPIA 812, HPLC 223 26 
4/2.2 Chronic rcjection; corticosteroid FPIA 325, HPLC 125 57 
morbidity: hypertension, delayed 
growth, migraines, behavioral 
problems 
5/12.9 Chronic rejection FPIA 915, HPLC 235 45 
6/7.11 Corticosteroid morbidity: hypertcnsion. FPIA 292, HPLC 91 58 
behavioral problems 
7/l.10 Cnrticosteroid morbidity: hyperlipidemia, FPIA 1,235, HPLC 371 34 
delayed growth 
CyA - cyclosporine A: FPIA = whole blood fluorescence polarization immunoassay; HPLC = high pressure liquid 
chromatography; Pt - patient; Tx transplantation. 
triple-drug immune suppression with cyclosporine, corticoste- 
roids and azathioprine (9,12). Study patients were chosen to 
undergo the switch to FK 506 because of persistent cellular 
rejection on endomyocardial biopsy when prednisone was 
tapered (4) or significant morbidity related to cyclosporine and 
prednisone, orboth (4). The time between transplantation a d 
the switch to FK 506 immunosuppression ranged from 9 to 58 
months (mean [_+SD] 35 _+ 19). Table 1 details patient 
demographic nformation and the reason for the immunosup- 
pression switch in each patient. 
The first five patients were hospitalized for the switch to FK 
506 so that blood pressure, urine output, serum blood urea 
nitrogen, serum creatinine, serum electrolytes, erum glucose 
and plasma drug levels could be monitored closely. The 
remaining two patients underwent the switch to FK 506 on a 
closely supervised outpatient basis in the Pittsburgh area. The 
designated rug protocol is outlined in Table 2. Informed 
consent was obtained from all patients and their families 
before the change in immunosuppressive agents. 
Episodes of rejection were monitored by endomyocardial 
biopsy 2 weeks after the switch to FK 506 and after each 
reduction of the corticosteroid osage. Major rejection epi- 
sodes were defined as histologic evidence of significant inter- 
stitial lymphocyte infiltration or myocyte necrosis, ISHLT 
classification grades 2to 3B. Pathologists grading the degree of 
rejection on surveillance biopsy specimens obtained after the 
Table 2. Summary ofDrug Protocol Used to Switch From 
Cyclosporine toFK 506 
1. Discontinue CyA 72 h before starting FK 5(16 
2. Initiate FK 506:0.2 mg/kg per day BID dosing 
3. Maintain all other immune suppression 
4. Monitor renal function, potassium and glucose 
5. Target FK 506 level: 0.5 to 1.5 ng/ml 
BID ~ twice a day; CyA - cyclosporine A. 
switch had no knowledge of the type of immunosuppression 
used. 
Allograft function determination was followed by right 
heart catheterization, echocardiography and electrocardio- 
graphy at the time of endomyocardial biopsy. Patients under- 
went monthly laboratory evaluation, including FK 506 plasma 
level, complete blood count and differential, renal function 
tests, serum electrolytes, erum glucose and liver function tests, 
including alanine aminotransferase, aspartate aminotransfer- 
ase, gamma-glutamyl transferase, alkaline phosphatase and 
total/direct bilirubin. Complete lipid panels, including total 
cholesterol, low density lipoprotein (LDL), high density li- 
poprotein and triglyceride levels, were performed in all pa- 
tients at 3- to 6-month intervals. 
After the switch from cyclosporine to FK 506-based im- 
munotherapy all patients were continued on maintenance 
prednisone at a dose of 0.1 to 0.3 mg/kg body weight per day. 
This subset of pediatric heart ransplant recipients included six 
of seven patients who could not be weaned from corticoste- 
roids because of evidence of ongoing rejection. The prednisone 
dose was decreased by 50% increments every 3 months after a 
negative biopsy result (ISHLT grades 1A and 1B only). Pred- 
nisone was discontinued from a dosage of 2.5 mg or 0.1 mg/kg. 
All seven patients included in this study were treated 
initially with cyclosporine, azathioprine and corticosteroids for 
9 to 58 months (mean [_+SD] 35 + 19) after heart ransplan- 
tation, and they were continued on their maintenance dose of 
azathioprine after the switch to FK 506. Prednisone was 
weaned and discontinued first. If patients continued to have no 
signs of rejection on endomyocardial biopsy, azathioprine was 
then stopped. Currently, azathioprine has been discontinued in 
five of seven patients, and will soon be stopped in the 
remaining two. 
Statistics. The Student  test for paired observations was 
used to compare differences between triple-drug suppression 
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Table 3. Summary ofRight Heart Hemodynamic and Echocardiographic Data From Pediatric Patients 9to 12 Months Before and After the 
Switch to FK 506 Immunosuppression 
CyA FK 506 
Range Mean _+ SD Range Mean -+ SD p Value 
Echocardiographic Data 
Left ventricular shortening fraction 0,30-0.49 0.36 _+ 0.03 0.30-0.41 0.36 _+ 0.03 0,77 
Interventricular septal thickness (ram) 6-12 8.7 _+ 1.4 6-10 9 _+ 0.9 0.42 
Left ventricular posterior wall thickness (ram) 6-10 8.4 + 1.4 6-11 8.7 _+ 1.3 0.65 
Left ventricular end-diastolic dimension (ram) 30-54 41 + 6 3(I-54 41 _+ 7 0.96 
Catheterization Data 
Pulmonary artery wedge pressure (ram Hg) 5-16 8.8 -- 1.6 5-15 9.1 _+ 2.7 0.21 
Mean right atrial pressure (ram Hg) 1-7 4.1 + 0.9 1-8 4.5 _+ 1.7 0.13 
Cardiac index (liters/min per m 2) 2.3-5.3 3.8 _+ 1.1 2.5-5.1 3.9 _+ 0.8 0.45 
CyA - cyclosporine A. 
and FK 506 mean values. Each patient served as his or her own 
control after the switch in immunosuppressive agents; how- 
ever, because of the small sample size, statistical analysis 
should be viewed with caution. Results are reported as mean 
value _+ SD, and p < 0.05 was considered significant. 
Results 
Allograft function. All seven patients maintained stable 
allografl function after being switched to FK 506. Table 3 
shows right heart hemodynamic and echocardiographic data 9 
to 12 months before and after the switch to FK 506. There has 
been no graft loss or documented coronary artery disease in 
our study patients. 
AllograR rejection. Endomyocardial biopsy results for all 
seven patients are presented inFigure 1. In the first 6 months 
after the change to FK 506, there were six episodes of rejection 
(ISHLT grades 2 to 3A) in seven patients. Five episodes 
resolved with a dose increase in FK 506, and only one required 
treatment with intravenous corticosteroids. In fact, as noted in 
Figure 1, there have been only two episodes of acute rejection 
that required treatment with intravenous corticosteroids since 
the switch to FK 506-based immune suppression. One was in 
the initial period after the switch to FK 506 in a patient with 
chronic rejection, and the second was associated with a pa- 
tient's noncompliance with FK 506. During the entire 
follow-up time (mean follow-up 24 months, range 15 to 41), 
there have been no episodes of significant acute rejection when 
the FK 506 level was within the therapeutic range of 0.5 to 
1.5 ng/ml. All seven patients have been weaned from pred- 
nisone and are free of the corticosteroid portion of their 
immune suppression. With the discontinuation f long-term 
oral prednisone, the four patients who were switched to FK 
506 because of corticosteroid morbidity had a resolution of 
Cushingoid features, migraine headaches, growth delay and 
behavioral problems. 
Complications of immune suppression. Hypertension. Six 
(85%) of seven of the patients required one or more antihy- 
pertensive medications tocontrol blood pressure while receiv- 
ing triple-drug immunosuppression. Since switching to FK 506 
antihypertension medication has been discontinued in all seven 
patients (Table 4). In one patient, hypertension resurfaced in
association with declining renal function 2years after switching 
to FK 506 immune suppression and 6 years after transplanta- 
tion. 
Hyperlipidemia. When immunotherapy included cyclospo- 
rine and corticosteroids, 71% of our study group had serum 
cholesterol and triglyceride levels >95th percentile for age 
(12). Since the switch to FK 506, all patients have had a 
decrease in the mean values of total serum cholesterol, trig- 
lycerides and LDL levels (Table 4). Total cholesterol values 
during triple-drug immunosuppression ranged from 161 to 
263 mg/dl (mean 217 [SD 35.6]) and decreased to 95 to 
193 mg/dl (mean 149 [SD 34.1]) during FK 506 therapy. 
Triglyceride levels before the switch were 83 to 271 mg/dl 
(mean 193 [SD 73.2]) and decreased to80 to 216 mg/dl (mean 
127 [SD 47]) after the switch. Low density lipoprotein choles- 
terol ranged from 85 to 193 mg/dl (mean 143 [SD 35.6]) before 
the switch and from 41 to 141 mg/dl (mean 97 [SD 33.6]) after 
the change to FK 506 therapy. 
Renal function. Renal function has been monitored closely. 
One year after the switch to single-drug immunosuppression 
with FK 506 there has been no statistically significant increase 
in blood urea nitrogen or creatinine values (Table 4). Mean 
blood urea nitrogen values on triple-drug immunosuppression 
1 year before the switch were 14 to 43 mg/dl (mean 28 [SD 9]) 
and increased to 22 to 37 mg/dl (mean 30 [SD 6]) after the 
switch to FK 506. Mean creatinine ranged from 0.5 to 1.4 mg/dl 
(mean 1.1 [SD 0.37]) before the switch to FK 506 and 
increased to 0.8 to 1.6 mg/dl (mean 1.26 [SD 0.26]) 1 year after 
the change in immunosuppression. Neither the increase in 
mean blood urea nitrogen or the increase in mean creatinine 
was statistically significant (p = 0.59 and p = 0.37, respectively). 
Malignancy. As shown in Figure 1, Patient 1 developed 
symptomatic posttransplant lymphoproliferative disease -1 
year after being switched to FK 506. This lymphoid tumor is 
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PATIENT #1 
PATIENT #2 
PATIENT# 3 
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PATIENT #6 
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PATIENT #7 
I= JD~D]  
A :~FK506 
~ : .  Methylprednisolone 
• PTLD 
D: ~ Maintenance Immunosuppression 
• - Subtherapeutic FK506 Levels 
v/// . ,a EMB Grade 0-1B 
I EMB Grade 2-3A 
48 42 36 30 24 18 12 6 ,~ 6 12 18 24 30 36 42 
FK 506 Switch Follow-up Time in Months 
Figure 1. Endomyocardial biopsy (EMB) results before and after 
immune suppression was changed to FK 506. PTLD = posttransplant 
lymphoproliferative disease. 
associated with Epstein-Barr viral infection in immunocom- 
promised hosts. Typically, the tumor regresses with reduction 
of immunosuppression alone, as it did in this patient. 
Discussion 
In October 1989 a prospective clinical trial was begun using 
FK 506 and low-dose steroids as the sole immunosuppression 
regimen in patients undergoing orthotopic ardiac transplan- 
tation (10). Results of that study were encouraging, particu- 
larly in the pediatric patients who previously were particularly 
troublesome compared with their adult counterparts in con- 
trolling allograft rejection. Also noted in that trial was a new 
degree of flexibility in immunosuppressant management with 
the ability to reverse pisodes of grade 2 to 3A rejection by 
merely increasing the oral dosage of FK 506. In addition, 80% 
of the study patients were successfully weaned from cortico- 
steroids and tolerated FK 506 with minimal adverse ffects. 
Approximately 10% to 15% of our pediatric heart trans- 
plant recipients who had undergone transplantation before 
October 1989 and were treated with traditional triple-drug 
immunosuppression experienced persistent allograft rejection 
when attempts were made to taper or discontinue corticoste- 
roids. Several of these patients were also experiencing morbid- 
ity secondary to cyclosporine and corticosteroids, uch as 
hypertension, hyperlipidemia, obesity, migraine headaches and 
behavioral problems. It was in this context hat we decided to 
switch these patients from cyclosporine to FK 506-based 
immune suppression. 
Allograft rejection. Nine episodes of rejection (ISHLT 
grade 2 to 3B) occurred in six allografts after the switch from 
cyclosporine to FK 506 during the follow-up period of 170 
months. These episodes all occurred when FK 506 levels were 
subtherapeutic, and most were treated with augmented dosing 
of FK 506 alone. Only two episodes were considered severe 
enough to require intravenous methylprednisolone. Currently, 
all patients are free of the corticosteroid portion of their 
Table 4, Antihypertensive Medications, Renal Function and Serum Lipid Values in the Study Patients Before and After the Switch in 
Immunosuppression 
Before Switch After Switch 
Renal Renal 
Function Serum Lipid LeveIs Function Serum Lipid Levels 
Antihypertensivc Antihypertensive 
Pt No. Medication BUN Cr T. Chol TG LDL Medication BUN Cr T. Chol TG LDL 
1 Captopril 29 1.1 161 270 85 None 29 1.4 95 107 4l 
2 Diltiazem 14 0.5 196 83 126 None 36 1.3 145 80 93 
3 Captopril 29 1.4 263 233 193 None 22 1.1 193 216 14l 
4 Nifedipinc 43 1.4 260 271 173 Nifedipine 37 1.4 178 163 129 
5 Captopril; cardiozem 24 1.2 216 129 141 None 30 1.2 125 97 75 
6 Captopril 33 1.4 210 217 124 None 34 1.6 172 117 109 
7 None 23 0.7 213 151 157 None 23 0.8 136 106 92 
Median 29 1.2 213 217 141 30 1.3 145 107 93 
Mean 28 1.11) 217 193 143 30 1.26 149 127 97 
p value 0.59 0.37 0.003 0.06 0.03 
BUN = blood urea nitrogen; Cr = crcatinine; LDL = low density lipoprotein; Pt = patient: T. Chol = total cholesterol; TG = triglyceride. 
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immunosuppressive regimen. The need for corticosteroids as 
part of maintenance immune suppression i children has been 
questioned in at least three reported studies (13-15). Despite 
these observations, our experience has identified a group of 
cardiac allograft recipients who have required corticosteroids 
as part of their immune suppression regimen. The present 
study has identified the effectiveness of FK 506 immune 
suppression i  this small subset of patients. 
Allograft function. We used serial right heart catheteriza- 
tion and echocardiography to document s able allograft func- 
tion during and after the switch in immune suppression 
regimen. Comparison of hemodynamic data, cardiac index and 
echocardiographic variables of allograft function before and 
up to 3 years after the switch to FK 506 indicated no decline in 
overall graft function. 
Hypertension and hyperlipidemia. Previous studies have 
documented a 40% to 70% incidence of hypertension i
transplant recipients receiving cyclosporine with or without 
corticosteroids (1,10). Not only does the increased afterload 
from hypertension adversely affect he transplanted heart, but 
drugs used for treatment, such as angiotensin-converting e -
zyme inhibitors, also may threaten already compromised renal 
function (16). All seven of our patients were able initially to 
discontinue one or more antihypertensive medications after 
the switch to FK 506 as a single immunosuppressive agent. The 
switch to FK 506 allowed resolution of corticosteroid-induced 
hypertension a d hypercholesterolemia. Uz rk et al. (2) studied 
hypercholesterolemia after cardiac transplantation i  children 
receiving prednisone, cyclosporine and azathioprine and found 
that within 2 to 12 months (mean 8.5) after cardiac transplanta- 
tion, 12 (86%) of 14 had a total serum cholesterol level above the 
90th percentile for age by Bogalusa criteria (13) and > 190 mg/dl. 
They concluded that hyperlipidemia, specifically hypercholester- 
olemia, is a common problem in children >2 years of age after 
cardiac transplantation. Mean serum cholesterol and triglyceride 
values were above the 95th percentile for age in 71% of our study 
patients when immunosuppression ncluded cyclosporine and 
prednisone; after the switch to FK 506, each patient had a 
decrease intotal cholesterol, triglyceride and HDL levels. Gao et 
al. (6) studied the clinical and laboratory correlates of accelerated 
coronary artery disease in adult cardiac transplant patients and 
also noted that elevated plasma triglyceride l vels were a signifi- 
cant predisposing factor for the development of posttransplant 
coronary artery disease. 
Renal function. The clinical trial of FK 506 in pediatric 
cardiac transplant patients at the University of Pittsburgh 
found that renal dysfunction i these patients had been modest 
(12). Each of our seven patients had a mild increase in blood 
urea nitrogen and creatinine values 1 year after the switch to 
FK 506, but, this increase was not statistically significant. 
Experience with both FK 506 and cyclosporine has shown 
similar nephrotoxicity profiles (16,17). Within I year after 
transplantation serum creatinine l vels double, which is out of 
proportion to somatic growth regardless of immune suppres- 
sion. One year after the switch to FK 506-based immune 
suppression there was no statistically significant change in 
blood urea nitrogen or creatinine values in any of our seven 
study patients. Currently two patients have moderate to severe 
renal dysfunction, which was present after several years of 
cyclosporine-based immune suppression regimens. Renal dys- 
function continued to progress after the switch to FK 506. Both 
of these patients will require renal transplantation in the 
future. We are concerned about long-term renal function in 
patients taking both cyclosporine and FK 506. Differences in 
long-term renal function in patients managed on cyclosporine 
versus FK 506 are not known. 
Summary and conclusions. FK 506 is an alternative immu- 
nosuppressive agent for patients experiencing ongoing rejec- 
tion or significant morbidity from cyclosporine and corticoste- 
roids. Although our study is limited by its small size, all 
patients were able to switch successfully to FK 506 with no 
increase in the incidence of rejection or decline in allograft 
function. We speculate that the reason that patients were able 
to do well with FK 506 alone may be related to its substantial 
immunosuppressive effect, shown in vitro to be greater than 
that of cyclosporine A (18). Hypertension and hyperlipidemia 
improved when cyclosporine and corticosteroids could be 
eliminated from the immune suppression regimen. Other side 
effects econdary to corticosteroids, uch as obesity, migraine 
headaches and behavioral problems resolved after discontinu- 
ation of long-term oral prednisone. The adverse ffects of FK 
506 in our study patients were mild and manageable. This 
preliminary study suggests that immunosuppression with FK 
506 may be a feasible alternative ina similar subset of pediatric 
patients. Further studies, including a larger randomized 
double-blind investigation ofpatients throughout the pediatric 
age range, will be important for future management. 
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